TOWA PHARMA. CO.

Research TOWA PHARMA. CO. (6QC) on Bullrun: valuation model: 29.5% overvalued, market cap EUR 1.00B, P/E 35.2, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker6QC
• ExchangeF
• CountryJapan
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Valuation signal29.5% overvalued
• Market capEUR 1.00B
• P/E35.2
• Dividend yield2.3%
• Financial periodFY2025
• RevenueEUR 259.59B
• Revenue growth13.9%
• Net incomeEUR 18.99B
• Free cash flow-EUR 7.82B
• Gross margin36.5%

Valuation Snapshot

Bullrun's latest valuation model marks TOWA PHARMA. CO. as 29.5% overvalued; latest market cap is EUR 1.00B; P/E is 35.2; dividend yield is 2.3%.

About TOWA PHARMA. CO.

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare;

Frequently asked questions

Is TOWA PHARMA. CO. overvalued or undervalued?

Bullrun's valuation model currently marks TOWA PHARMA. CO. as 29.5% overvalued.

What is TOWA PHARMA. CO.'s market cap?

TOWA PHARMA. CO.'s market capitalization is EUR 1.00B.

What is TOWA PHARMA. CO.'s P/E ratio?

TOWA PHARMA. CO.'s price-to-earnings (P/E) ratio is 35.2.

Does TOWA PHARMA. CO. pay a dividend?

TOWA PHARMA. CO. has a dividend yield of 2.3%.

What does TOWA PHARMA. CO. do?

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas.